{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:33:38Z","timestamp":1723466018065},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.2169\/internalmedicine.7098-21","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T22:08:36Z","timestamp":1621634916000},"page":"3369-3376","source":"Crossref","is-referenced-by-count":2,"title":["Association of the Low-density Lipoprotein Cholesterol\/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment"],"prefix":"10.2169","volume":"60","author":[{"given":"Noriyuki","family":"Akutsu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Teine Keijinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saiseikai Otaru Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kushiro City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tsujisaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tenshi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Isshiki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yawata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hakodate Goryoukaku Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Satozuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Ban","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Shirakabadai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeya","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, JR Sapporo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Teishinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyasu","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Teishinkai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Nakachi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tochigi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Gekakinen Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Obihiro Kyokai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Muroran City General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Wagatsuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunao","family":"Numata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2: 161-176, 2017."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17: 1062-1068, 2017.","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66: 389-397, 2017.","DOI":"10.1002\/hep.29081"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378: 354-369, 2018.","DOI":"10.1056\/NEJMoa1702417"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 53: 557-565, 2018.","DOI":"10.1007\/s00535-017-1391-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53: 566-575, 2018.","DOI":"10.1007\/s00535-017-1396-0"},{"key":"7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"7. Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 67: 505-513, 2018.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Popescu C-I, Riva L, Vlaicu O, Farhat R, Rouill\u00e9 Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology 3: 892-921, 2014.","DOI":"10.3390\/biology3040892"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50: 1030-1037, 2009.","DOI":"10.1002\/hep.23219"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Beig J, Orr D, Harrison B, Gane E. Hepatitis C virus eradication with new interferon-free treatment improves metabolic profile in hepatitis C virus-related liver transplant recipients. Liver Transpl 24: 1031-1039, 2018.","DOI":"10.1002\/lt.25060"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 53: 857-863, 2018.","DOI":"10.1080\/00365521.2018.1473486"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chaudhury CS, Sheehan J, Chairez C, et al. No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis 217: 47-50, 2017.","DOI":"10.1093\/infdis\/jix517"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chida T, Kawata K, Ohta K, et al. Rapid changes in serum lipid profiles during combination therapy with daclatasvir and asunaprevir in patients infected with hepatitis C virus genotype 1b. Gut Liver 12: 201-207, 2018.","DOI":"10.5009\/gnl17179"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. El Sagheer G, Soliman E, Ahmad A, Hamdy L. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med 13: 1435124, 2018.","DOI":"10.1080\/19932820.2018.1435124"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Endo D, Satoh K, Shimada N, Hokari A, Aizawa Y. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol 23: 2355-2364, 2017.","DOI":"10.3748\/wjg.v23.i13.2355"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gitto S, Cicero AFG, Loggi E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol 17: 64-75, 2018.","DOI":"10.5604\/01.3001.0010.7536"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One 11: e0163644, 2016.","DOI":"10.1371\/journal.pone.0163644"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Inoue T, Goto T, Iio E, et al. Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. Hepatol Res 48: E203-E212, 2018.","DOI":"10.1111\/hepr.12970"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther 21: 81-88, 2017.","DOI":"10.3851\/IMP3094"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 61: 790-801, 2015.","DOI":"10.1002\/hep.27424"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol 8: 1557-1563, 2016.","DOI":"10.4254\/wjh.v8.i35.1557"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir\/elbasvir or ledipasvir\/sofosbuvir treatment against chronic HCV infection. Gut 67: 1342-1350, 2018.","DOI":"10.1136\/gutjnl-2017-313832"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Townsend K, Meissner EG, Sidharthan S, et al. Interferon-free treatment of hepatitis C virus in HIV\/hepatitis C virus-coinfected subjects results in increased serum low-density lipoprotein concentration. AIDS Res Hum Retroviruses 32: 456-462, 2016.","DOI":"10.1089\/aid.2015.0170"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Younossi ZM, Stepanova M, Estep M, et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol 64: 29-36, 2016.","DOI":"10.1016\/j.jhep.2015.08.027"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes\/macrophages\/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 286: 10847-10855, 2011.","DOI":"10.1074\/jbc.M110.217653"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sarcar B, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Virology 322: 51-60, 2004.","DOI":"10.1016\/j.virol.2004.01.008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 68: 2857-2866, 2016.","DOI":"10.1002\/art.39808"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 69: 741-746, 2010.","DOI":"10.1136\/ard.2008.104844"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Chen QJ, Lai HM, Chen BD, et al. Appropriate LDL-C-to-HDL-C ratio cutoffs for categorization of cardiovascular disease risk factors among Uygur adults in Xinjiang, China. Int J Environ Res Public Health 13: 235, 2016.","DOI":"10.3390\/ijerph13020235"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Liu L, Yin P, Lu C, et al. Association of LDL-C\/HDL-C ratio with stroke outcomes within 1 year after onset: a hospital-based follow-up study. Front Neurol 11: 408, 2020.","DOI":"10.3389\/fneur.2020.00408"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 31: 891-903, 2014.","DOI":"10.1007\/s12325-014-0138-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ambrosino P, Tarantino L, Criscuolo L, Nasto A, Celentano A, Di Minno MN. The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. Thromb Haemost 116: 958-966, 2016.","DOI":"10.1160\/TH16-03-0185"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Hepatitis C virus infection and risk of venous thromboembolism: a systematic review and meta-analysis. Ann Hepatol 16: 514-520, 2017.","DOI":"10.5604\/01.3001.0010.0279"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7098-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T03:20:21Z","timestamp":1636168821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7098-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7098-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"7098-21"}}